According to These devices represent new technologies that are increasingly favored for their minimally invasive nature.
According to the research, the transcatheter aortic heart valve replacement (TAVR) device,
"Competitors are seeking to replicate the success of
Manufacturers are also in the process of developing transcatheter mitral valve replacement devices designed to be implanted in the native mitral valve. Currently, clinical experience is limited with these devices, although this device is expected to see continued development resulting in eventual commercial approval in the US around 2021. Transcatheter mitral valve repair and replacement technologies will likely compete for patients to some extent, although as the two products become more established, it is likely that they will be largely indicated for different patient subsets.
((Comments on this story may be sent to firstname.lastname@example.org))
These devices represent new technologies that are increasingly favored for their minimally invasive nature.